source
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…
- Genetic Testing Helps Refine Kidney Disease Trial Design, Says Natera ExpertIn a sponsored episode of The Top Line, Dr. Ronen Schneider, Natera's medical director of renal genetics, explains how genotype‑defined kidney disease data can improve clinical trial design. He not…